Menu Close

Can we speed along HIV treatment with lower toxicity?

When it comes to the latest news on HIV treatment, there are some very hopeful research results about newly developed drugs and therapies, but most of them have significant side effects and toxicities in long-term use. Plus magazine‘s contributor Jeannie Wraight, on her latest article about HIV treatment, focused on the importance of prioritizing therapeutics based on low toxicity-compounds, like First Health Pharmaceuticals’ DDX3 RNA Helicase inhibitors, that are specifically designed with attention to a reduction in side effects in publicly sponsored clinical trials and NIH funded grants.

Read the full article:


Loader Loading...
EAD Logo Taking too long?
Reload Reload document
| Open Open in new tab